Therapeutic efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015-2016.
Therapeutic efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015-2016.
复制标题
DOI：
10.1186/s12936-021-03760-9
复制
发表时间：
2021-05-25
期刊：
影响因子：
3
通讯作者：
Koita OA
中科院分区：
文献类型：
--
作者：
Diarra Y;Koné O;Sangaré L;Doumbia L;Haidara DBB;Diallo M;Maiga A;Sango HA;Sidibé H;Mihigo J;Nace D;Ljolje D;Talundzic E;Udhayakumar V;Eckert E;Woodfill CJ;Moriarty LF;Lim P;Krogstad DJ;Halsey ES;Lucchi NW;Koita OA
马里国家疟疾防治方案推荐的目前治疗无并发症疟疾的一线药物是蒿甲醚-苯芴醇和青蒿琥酯-阿莫地喹。从2015年到2016年，在马里Sélingué进行了一项体内研究，以评估AL和ASAQ的临床和寄生虫学反应。招募年龄在6 - 59个月之间的单纯恶性疟原虫感染和2000- 200，000无性寄生虫/μL血液的儿童，随机分配到AL或ASAQ，并随访42天。第28天和第42天未校正和PCR校正的疗效结果。计算了使用桑格测序评估Pfk 13、Pfmdr 1和Pfcrt基因中的已知耐药标记。共入组449例患者：AL组225例，ASAQ组224例。第28天的未校正疗效为83.4% AL组（95% CI 78.5-88.4%）和93.1%（95% CI 89.7-96.5%）。第28天符合方案PCR校正的疗效为91.0%在AL组中为86.0-95.9%，在ASAQ组中为97.1%（93.6-100%）ASAQ对于上述每种疗效结果均显著（p < 0.05）优于AL。在Pfk 13基因中未发现与青蒿素耐药性相关的突变。总体而言，Pfmdr 1，N86等位基因和NFD单倍型是最常见的。在AL组中，NFD单倍型在治疗后分离株中比治疗前分离株中显著更普遍（p < 0.01），但在ASAQ组中并非如此。研究结果表明，AL和ASAQ仍然有效地治疗马里Sélingué的无并发症疟疾。在线版本包含补充材料，可通过10.1186/s12936-021-03760-9获得。
The current first-line treatments for uncomplicated malaria recommended by the National Malaria Control Programme in Mali are artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ). From 2015 to 2016, an in vivo study was carried out to assess the clinical and parasitological responses to AL and ASAQ in Sélingué, Mali. Children between 6 and 59 months of age with uncomplicated Plasmodium falciparum infection and 2000–200,000 asexual parasites/μL of blood were enrolled, randomly assigned to either AL or ASAQ, and followed up for 42 days. Uncorrected and PCR-corrected efficacy results at days 28 and 42. were calculated. Known markers of resistance in the Pfk13, Pfmdr1, and Pfcrt genes were assessed using Sanger sequencing. A total of 449 patients were enrolled: 225 in the AL group and 224 in the ASAQ group. Uncorrected efficacy at day 28 was 83.4% (95% CI 78.5–88.4%) in the AL arm and 93.1% (95% CI 89.7–96.5%) in the ASAQ arm. The per protocol PCR-corrected efficacy at day 28 was 91.0% (86.0–95.9%) in the AL arm and 97.1% (93.6–100%) in the ASAQ arm. ASAQ was significantly (p < 0.05) better than AL for each of the aforementioned efficacy outcomes. No mutations associated with artemisinin resistance were identified in the Pfk13 gene. Overall, for Pfmdr1, the N86 allele and the NFD haplotype were the most common. The NFD haplotype was significantly more prevalent in the post-treatment than in the pre-treatment isolates in the AL arm (p < 0.01) but not in the ASAQ arm. For Pfcrt, the CVIET haplotype was the most common. The findings indicate that both AL and ASAQ remain effective for the treatment of uncomplicated malaria in Sélingué, Mali. The online version contains supplementary material available at 10.1186/s12936-021-03760-9.
登录
查看更多内容
影响因子：
3
作者：
Otienoburu, Sabina Dahlstrom;Maiga-Ascofare, Oumou;Houze, Sandrine
通讯作者：
Houze, Sandrine
DOI：
10.1016/s1473-3099(17)30365-1
发表时间：
2017-12
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Koita OA;Sangaré L;Miller HD;Sissako A;Coulibaly M;Thompson TA;Fongoro S;Diarra Y;Ba M;Maiga A;Diallo B;Mushatt DM;Mather FJ;Shaffer JG;Anwar AH;Krogstad DJ
通讯作者：
Krogstad DJ
影响因子：
6.7
作者：
Talundzic E;Okoth SA;Congpuong K;Plucinski MM;Morton L;Goldman IF;Kachur PS;Wongsrichanalai C;Satimai W;Barnwell JW;Udhayakumar V
通讯作者：
Udhayakumar V
影响因子：
9.3
作者：
Denoeud-Ndam L;Dicko A;Baudin E;Guindo O;Grandesso F;Diawara H;Sissoko S;Sanogo K;Traoré S;Keita S;Barry A;de Smet M;Lasry E;Smit M;Wiesner L;Barnes KI;Djimde AA;Guerin PJ;Grais RF;Doumbo OK;Etard JF
通讯作者：
Etard JF
影响因子：
3
作者：
Diakite, Seidina A. S.;Traore, Karim;Diakite, Mahamadou
通讯作者：
Diakite, Mahamadou